F. Markus Leweke
Central Institute of Mental Health · University of Cologne
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name F. Markus Leweke as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02926859 · Enhancing Recovery in Early SchizophreniaCentral Institute of Mental Health, Mannheim · active not recruiting · Schizophrenia · principal investigator
- Ph1NCT02492074 · Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET StudyCentral Institute of Mental Health, Mannheim · withdrawn · Healthy Volunteers, Modeling Psychosis · principal investigator
- Ph2NCT02088060 · A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic PatientsCentral Institute of Mental Health, Mannheim · terminated · Schizophrenia · principal investigator
- Ph1NCT00916201 · Evaluation Study of New Compounds With Potential Use in SchizophreniaCentral Institute of Mental Health, Mannheim · withdrawn · Schizophrenia · principal investigator
- Ph2/Ph3NCT00637234 · Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute SchizophreniaUniversity of Cologne · completed · Schizophrenia · study director
- Ph2NCT00309413 · A Clinical Trial on the Antipsychotic Properties of CannabidiolUniversity of Cologne · completed · Schizophrenia, Psychotic Disorders · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:28 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.Transl Psychiatry · 2012777 citationsRCR 28.0
- Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia.Neuroimage · 201390 citationsRCR 3.3
- Treatment of alcohol withdrawal syndrome with gabapentin.Pharmacopsychiatry · 199973 citationsRCR 2.5
- Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls.J Proteomics · 201269 citationsRCR 2.1
- Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial.J Clin Psychopharmacol · 200354 citationsRCR 1.8
- 52 citationsRCR 1.8
- Visual 3D illusion: a systems-theoretical approach to psychosis.Eur Arch Psychiatry Clin Neurosci · 199641 citationsRCR 1.4
- Clinical use of phosphorylated proteins in blood serum analysed by immobilised metal ion affinity chromatography and mass spectrometry.J Proteomics · 201222 citationsRCR 0.7
- Gabapentin's acute effect on mood profile -- a controlled study on patients with alcohol withdrawal.Prog Neuropsychopharmacol Biol Psychiatry · 200713 citationsRCR 0.5
- Oxcarbazepine as an adjunct for schizophrenia.Am J Psychiatry · 20049 citationsRCR 0.3